Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study

BMC Infectious Diseases

Research Article

Liang-Che Chang¹  Ching-Chih Hu²  Ching-Jung Liu²  Cheng-Hung Chien²  Rong-Nan Chien²  Li-Wei Chen²  Chih-Lang Lin² 

[1] Department of Pathology, Chang Gung Memorial Hospital, 222 Mai-Chin Road, 20401, Keelung, Taiwan;Liver Research Unit, Chang Gung Memorial Hospital, 222 Mai-Chin Road, 20401, Keelung, Taiwan;

关键词: Advanced fibrosis;    Chronic hepatitis C;    Interleukin-28B;    rs8099917;    Sustained virologic response;   

DOI  :  10.1186/s12879-015-0888-x

 received in 2014-11-29, accepted in 2015-03-12,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundThe role of single nucleotide polymorphisms (SNPs) of interleukin (IL)-28B in predicting therapeutic response of pegylated interferon (peg-IFN) plus ribavirin (PR) for genotype 1 infected chronic hepatitis C patients with advanced fibrosis (AF) is limited. The aim of this study is to assess its role in predicting sustained virologic responses (SVR) to treatment.MethodsForty-two patients with biopsy proven hepatitis C virus (HCV) related AF (group A; Ishak fibrosis score, ≥4) and 126 sex- and HCV genotype-matched patients without AF (group B; Ishak fibrosis score, ≤3) were recruited into study. All patients received PR therapy for 24 weeks. Baseline and on-treatment clinical, virological and host factors were evaluated for treatment efficacy.ResultsThe SVR rate was significantly lower in group A than group B patients with genotype 1 infection (24% vs. 53.3%; p = 0.011). However, it was similar in those with genotype non-1 infection (76.5% vs. 76.5%; p = 1.0). IL-28B rs8099917 genotype TT is the strongest predictor for SVR in genotype 1 infection. Patients who had TT genotype and achieved RVR in group A had similar SVR rates with those in group B (44.4% vs. 53.3%; p = 0.614). One third of patients in group A developed hematological adverse effects and had required modified doses during antiviral therapy.ConclusionsIn HCV genotype 1 infected AF receiving 24 weeks of PR treatment, patients with IL28B rs8099917 genotype TT, achieving RVR had similar SVR rate with those without AF. In contrast, patients with IL-28B rs8099917 non-TT genotype without achieving RVR are suggested to stop therapy.

【 授权许可】

Unknown   
© Hu et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.